| 摘要 |
A biomarker is provided to be useful for monitoring methotrexate and determining harmfulness of the methotrexate, thereby being used as a tool for identifying toxicity action mechanism caused by the methotrexate. A biomarker for screening methotrexate includes a gene selected from the group consisting of Genebank NM_004759, Genebank AK122828, Genebank NM_003311, Genebank NM_003506, Genebank NM_005438, Genebank NM_030821, Genebank NM_016205, Genebank AK027210, Genebank NM_018367, Genebank M92424, Genebank NM_000826, Genebank BC036030, Genebank NM_004167, Genebank AB057597, Genebank D26070, Genebank NM_207111, Genebank NM_002511, Genebank NM_000575, Genebank NM_138961, Genebank NM_001024736, Genebank BC002726, Genebank NM_033131, Genebank BC030595, Genebank NM_000710, Genebank AK096323, Genebank NM_078467, Genebank NM_000425, Genebank NM_000899, Genebank NM_002562, Genebank CR594190, Genebank AL832585, Genebank NM_198859, Genebank NM_018667, Genebank NM_001295, Genebank NM_001911, Genebank NM_001759, Genebank NM_000641, Genebank S78234, Genebank AB209361, Genebank BX649005, Genebank AK127679, Genebank AK126462, Genebank NM_003013, Genebank NM_006162, Genebank BC008678, Genebank AK022486, Genebank NM_001315, Genebank BC026283, Genebank AK092791, Genebank BX648822, Genebank BC036078, Genebank L25664, Genebank NM_005419, Genebank CR598645, Genebank NM_031468, Genebank AL833391, Genebank BC033058, Genebank AK127004, Genebank NM_004064, Genebank NM_004360, Genebank BC031405, Genebank BC075814, Genebank M38056, Genebank AB209599, Genebank AY358836, Genebank NM_002758, Genebank NM_006614, Genebank NM_080425, Genebank NM_004526 Genebank L19315, Genebank NM_006120, Genebank NM_002760, Genebank AF041245, Genebank NM_000889, and Genebank AL136787. A total or a portion of the biomarker gene sequence or a complimentary strand molecule thereof is integrated into a DNA microarray chip. A method for screening volatile organic compounds comprises the steps of: (a) treating human bronchial epithelial cells with a compound to be tested; (b) isolating RNA respectively from the test group cells treated with the compound to be tested and control group cells; (c) labelling the test group and the control group, respectively, with a fluorescent material different from each other with synthesizing the RNA of the test group and the control group into cDNA; (d) hybridizing each the cDNA(s) labelled with the fluorescent material into the DNA microarray chip; (e) analyzing the reacted DNA microarray chip; and (f) comparing the expression degree of the biomarker from the data analyzed by the step(e) with that of the control group. |
